What is treatment success in cardiac resynchronization therapy?

Paul W. X. Foley, Francisco Leyva, Michael P. Frenneaux

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Cardiac resynchronization therapy (CRT) is an established treatment for symptomatic patients with heart failure, a prolonged QRS duration, and impaired left ventricular (LV) function. Identification of 'responders' and 'non-responders' to CRT has attracted considerable attention. The response to CRT can be measured in terms of symptomatic response or clinical outcome, or both. Alternatively, the response to CRT can be measured in terms of changes in surrogate measures of outcome, such as LV volumes, LV ejection fraction, invasive measures of cardiac performance, peak oxygen uptake, and neurohormones. This review explores whether these measures can be used in assessing the symptomatic and prognostic response to CRT. The role of these parameters to the management of individual patients is also discussed.

Original languageEnglish
Pages (from-to)v58-v65
Number of pages8
JournalEuropace
Volume11
Issue numberSuppl. 5
DOIs
Publication statusPublished - Nov 2009

Keywords

  • cardiac resynchronization therapy
  • mortality
  • responders
  • chronic heart-failure
  • brain natriuretic peptide
  • long-term survival
  • diastolic ventricular interaction
  • randomized controlled-trials
  • exercise oxygen-consumption
  • surrogate end-points
  • 6-minute walk test
  • care-HF trial
  • ischemic cardiomyopathy

Cite this

Foley, P. W. X., Leyva, F., & Frenneaux, M. P. (2009). What is treatment success in cardiac resynchronization therapy? Europace, 11(Suppl. 5), v58-v65. https://doi.org/10.1093/europace/eup308

What is treatment success in cardiac resynchronization therapy? / Foley, Paul W. X.; Leyva, Francisco; Frenneaux, Michael P.

In: Europace, Vol. 11, No. Suppl. 5, 11.2009, p. v58-v65.

Research output: Contribution to journalArticle

Foley, PWX, Leyva, F & Frenneaux, MP 2009, 'What is treatment success in cardiac resynchronization therapy?', Europace, vol. 11, no. Suppl. 5, pp. v58-v65. https://doi.org/10.1093/europace/eup308
Foley, Paul W. X. ; Leyva, Francisco ; Frenneaux, Michael P. / What is treatment success in cardiac resynchronization therapy?. In: Europace. 2009 ; Vol. 11, No. Suppl. 5. pp. v58-v65.
@article{2b28e07fc88342cca30f6a82484d6c3d,
title = "What is treatment success in cardiac resynchronization therapy?",
abstract = "Cardiac resynchronization therapy (CRT) is an established treatment for symptomatic patients with heart failure, a prolonged QRS duration, and impaired left ventricular (LV) function. Identification of 'responders' and 'non-responders' to CRT has attracted considerable attention. The response to CRT can be measured in terms of symptomatic response or clinical outcome, or both. Alternatively, the response to CRT can be measured in terms of changes in surrogate measures of outcome, such as LV volumes, LV ejection fraction, invasive measures of cardiac performance, peak oxygen uptake, and neurohormones. This review explores whether these measures can be used in assessing the symptomatic and prognostic response to CRT. The role of these parameters to the management of individual patients is also discussed.",
keywords = "cardiac resynchronization therapy, mortality, responders, chronic heart-failure, brain natriuretic peptide, long-term survival, diastolic ventricular interaction, randomized controlled-trials, exercise oxygen-consumption, surrogate end-points, 6-minute walk test, care-HF trial, ischemic cardiomyopathy",
author = "Foley, {Paul W. X.} and Francisco Leyva and Frenneaux, {Michael P.}",
year = "2009",
month = "11",
doi = "10.1093/europace/eup308",
language = "English",
volume = "11",
pages = "v58--v65",
journal = "Europace",
issn = "1099-5129",
publisher = "Oxford University Press",
number = "Suppl. 5",

}

TY - JOUR

T1 - What is treatment success in cardiac resynchronization therapy?

AU - Foley, Paul W. X.

AU - Leyva, Francisco

AU - Frenneaux, Michael P.

PY - 2009/11

Y1 - 2009/11

N2 - Cardiac resynchronization therapy (CRT) is an established treatment for symptomatic patients with heart failure, a prolonged QRS duration, and impaired left ventricular (LV) function. Identification of 'responders' and 'non-responders' to CRT has attracted considerable attention. The response to CRT can be measured in terms of symptomatic response or clinical outcome, or both. Alternatively, the response to CRT can be measured in terms of changes in surrogate measures of outcome, such as LV volumes, LV ejection fraction, invasive measures of cardiac performance, peak oxygen uptake, and neurohormones. This review explores whether these measures can be used in assessing the symptomatic and prognostic response to CRT. The role of these parameters to the management of individual patients is also discussed.

AB - Cardiac resynchronization therapy (CRT) is an established treatment for symptomatic patients with heart failure, a prolonged QRS duration, and impaired left ventricular (LV) function. Identification of 'responders' and 'non-responders' to CRT has attracted considerable attention. The response to CRT can be measured in terms of symptomatic response or clinical outcome, or both. Alternatively, the response to CRT can be measured in terms of changes in surrogate measures of outcome, such as LV volumes, LV ejection fraction, invasive measures of cardiac performance, peak oxygen uptake, and neurohormones. This review explores whether these measures can be used in assessing the symptomatic and prognostic response to CRT. The role of these parameters to the management of individual patients is also discussed.

KW - cardiac resynchronization therapy

KW - mortality

KW - responders

KW - chronic heart-failure

KW - brain natriuretic peptide

KW - long-term survival

KW - diastolic ventricular interaction

KW - randomized controlled-trials

KW - exercise oxygen-consumption

KW - surrogate end-points

KW - 6-minute walk test

KW - care-HF trial

KW - ischemic cardiomyopathy

U2 - 10.1093/europace/eup308

DO - 10.1093/europace/eup308

M3 - Article

VL - 11

SP - v58-v65

JO - Europace

JF - Europace

SN - 1099-5129

IS - Suppl. 5

ER -